Full Press Release Details
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions.
ALT
Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions
Key Takeaway: Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions
Price reaction · baseline $5.92 (2024-06-17 close) · hit after-hours · 6 other ALT headline(s) in the window, move may be shared
day 0 close
-0.2%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+22%
120-day peak, hindsight
Typical move
10.2%
average across 8 past catalysts
Cash runway
~64 mo
Minimal dilution risk
Lead asset
ALT-801
Phase 2 · Obesity/Overweight